How is Livagen different from Vesugen?

Livagen (KEDA) and Vesugen (KED) share the same first three amino acids. Livagen adds an alanine at the C-terminus and targets liver and immune tissue, while Vesugen targets vascular endothelial cells. Despite the structural similarity, they appear to have different tissue specificities — a key claim of the Khavinson framework.

What is chromatin decondensation?

As cells age, portions of DNA become tightly packed (heterochromatin) and genes in those regions become silenced. Chromatin decondensation reverses this — reopening the DNA so that previously silenced genes can be read and expressed again. Livagen has been shown to do this in lymphocytes from elderly subjects.

Is Livagen FDA-approved?

No. Livagen is not FDA-approved and is not used in mainstream Western medicine. Research comes from the Khavinson bioregulator program at the Saint Petersburg Institute of Bioregulation and Gerontology.

Livagen

A synthetic tetrapeptide bioregulator (Lys-Glu-Asp-Ala) from the Khavinson system, studied for chromatin decondensation, hepatoprotection, and immune cell reactivation in aging.

PreliminaryLimited Data

What is Livagen?

Livagen is a synthetic tetrapeptide consisting of lysine, glutamic acid, aspartic acid, and alanine (Lys-Glu-Asp-Ala, or KEDA), developed by Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology. It is one of the most mechanistically characterized bioregulator peptides, with direct evidence of chromatin decondensation in human lymphocytes from elderly subjects. Livagen targets the liver, gastrointestinal tract, and immune system, and shares its first three amino acids with Vesugen (KED), differing only by the C-terminal alanine. With 9 PubMed-indexed publications, it has some of the strongest preclinical evidence for the chromatin-remodeling mechanism that underpins the entire Khavinson bioregulator theory.

Why People Talk About It

Chromatin reactivation and age-related gene silencing

Emerging

Hepatoprotection and liver function support

Preliminary

Immune cell reactivation in elderly

Preliminary

Digestive enzyme restoration in aging

Preliminary

Protein synthesis enhancement in aging hepatocytes

Preliminary

How It Works

Livagen works by reopening tightly packed DNA in aging cells. As we age, portions of our DNA become locked down and the genes there stop working. Livagen has been shown to reverse this process — specifically in immune cells and liver cells — reactivating genes involved in protein production, immune function, and digestive enzyme activity.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Generally well-tolerated in available studiesNo adverse effects reported in published research

Cautions

• Not FDA-approved
• No human clinical trials — evidence is from ex vivo human tissue and animal models
• Quality and purity vary by source
• Should be used under clinician guidance

What We Don't Know

No formal safety studies exist. The chromatin decondensation mechanism raises theoretical questions about unintended gene activation, though a study in elderly patients using multiple Khavinson peptides found no chromatin condensation abnormalities. Long-term effects are unknown.

Published Research

9 studies

The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.

ReviewPMID: 32362099

Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan.

PreclinicalPMID: 28948547

Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages.

PreclinicalPMID: 16075683

Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen.

PreclinicalPMID: 15926314

Effects of short peptides on lymphocyte chromatin in senile subjects.

PreclinicalPMID: 15085253

Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum.

PreclinicalPMID: 12942748

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

PreclinicalPMID: 12533768

Tissue-specific action of peptides in tissue culture of rats of various ages.

PreclinicalPMID: 12096446

Tissue-specific effects of peptides.

PreclinicalPMID: 11713572

Mechanism of Action

Livagen (Lys-Glu-Asp-Ala) induces deheterochromatinization — the conversion of tightly packed heterochromatin back to transcriptionally active euchromatin. In lymphocytes from elderly subjects (ages 75-88), it activated ribosomal genes, decondensed pericentromeric structural heterochromatin, and released genes repressed by age-related condensation, specifically affecting heterochromatic regions of chromosomes 1 and 9. In hepatocyte cultures, it enhanced protein synthesis rhythm and intensity, with stronger effects in aged cells. Oral administration in aged rats restored digestive enzyme activity (dipeptidases) toward young-animal levels, suggesting functional restoration of GI tissue. It resists degradation by small intestinal peptidases, supporting oral bioavailability. A 2020 review confirmed hepatoprotective and immunomodulatory effects, normalizing antioxidant markers and restoring liver function in hepatitis models, with strongest effects in aging organisms.

Evidence Snapshot

Overall Confidence30%

Human Clinical Evidence

None. No human clinical trials have been conducted with Livagen. However, ex vivo studies using lymphocytes from elderly human donors (ages 75-88) demonstrated chromatin reactivation and ribosomal gene activation (PMID: 12533768, 15085253). These are not clinical trials but do use primary human tissue.

Animal / Preclinical

Moderate. Oral Livagen restored digestive enzyme activity in aged rats toward young-animal levels (PMID: 16075683). Enhanced protein synthesis in hepatocyte cultures from aged rats (PMID: 15926314). Demonstrated hepatoprotective and immunomodulatory effects in hepatitis models (PMID: 32362099). Tissue-specific effects confirmed across liver, GI, and immune tissue (PMID: 11713572, 12096446).

Mechanistic Rationale

Strong for the chromatin mechanism — Livagen is arguably the best-characterized Khavinson peptide in terms of its core proposed mechanism. Direct visualization of heterochromatin decondensation in human lymphocytes and ribosomal gene activation provide concrete evidence for the epigenetic framework. The tissue-specificity mechanism (why KEDA targets liver/immune while KED targets vasculature) remains unexplained.

Forms & Administration

Livagen is available in capsule and injectable formats. Oral bioavailability is supported by its resistance to intestinal peptidase degradation. All peptides should only be used under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Use Cases & Evidence Levels

Chromatin reactivation and age-related gene silencing

Emerging50%

Hepatoprotection and liver function support

Preliminary30%

Immune cell reactivation in elderly

Preliminary30%

Digestive enzyme restoration in aging

Preliminary30%

Protein synthesis enhancement in aging hepatocytes

Preliminary30%

Safety Profile

Safety Information

Common Side Effects

Generally well-tolerated in available studiesNo adverse effects reported in published research

Cautions

• Not FDA-approved
• No human clinical trials — evidence is from ex vivo human tissue and animal models
• Quality and purity vary by source
• Should be used under clinician guidance

What We Don't Know

Published Research

9 studies

The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.

ReviewPMID: 32362099

Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan.

PreclinicalPMID: 28948547

Effect of peptide Livagen on activity of digestive enzymes in gastrointestinal tract and non-digestive organs in rats of different ages.

PreclinicalPMID: 16075683

Rhythm of protein synthesis in cultures of hepatocytes from rats of different ages. Norm and effect of the peptide livagen.

PreclinicalPMID: 15926314

Effects of short peptides on lymphocyte chromatin in senile subjects.

PreclinicalPMID: 15085253

Effect of new peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum.

PreclinicalPMID: 12942748

Effects of Livagen peptide on chromatin activation in lymphocytes from old people.

PreclinicalPMID: 12533768

Tissue-specific action of peptides in tissue culture of rats of various ages.

PreclinicalPMID: 12096446

Tissue-specific effects of peptides.

PreclinicalPMID: 11713572

Related Peptides

Epithalon

Preliminary

A synthetic tetrapeptide studied for its potential to activate telomerase and influence cellular aging.

Vesugen

Preliminary

A synthetic tripeptide bioregulator (Lys-Glu-Asp) from the Khavinson system, studied for vascular protection, endothelial function, and age-related cardiovascular decline.

Ovagen

Limited

A synthetic tripeptide bioregulator (Glu-Asp-Leu) from the Khavinson system, studied for liver tissue support, hepatoprotection, and gastrointestinal health.